Iinkcukacha ezithe xaxe ― Isixhosa

Urticarial vasculitis yimeko enqabileyo ephawulwe ngokuhlala ixesha elide okanye iziqendu eziphindaphindiweyo ze-hives. Ngelixa iimpawu zesikhumba zifana ne-hives ezingapheliyo, zizodwa ngenxa yokuba i-hives inamathela malunga neeyure ezingama-24 kwaye inokubangela amabala amnyama emva kokubuna. Nangona isoloko ibangelwa ngunobangela ongaziwayo, ngamanye amaxesha inokuqalwa ngamayeza athile, usulelo, izifo ezizimela ngokwazo, ukuphazamiseka kwegazi, okanye umhlaza. Ezinye izifundo ziye zayinxulumanisa ne-COVID-19 kunye ne-H1N1 flu. Isenokuchaphazela namanye amalungu omzimba njengezihlunu, izintso, imiphunga, isisu kunye namehlo. Nangona uhlobo oluthile lokuhlolwa kwezicubu lunokuqinisekisa ukuxilongwa, akusoloko kuyimfuneko. Unyango ngokuqhelekileyo luqala ngee-antibiotics, i-dapsone, i-colchicine, okanye i-hydroxychloroquine kwiimeko ezingenzima kakhulu. Kwiimeko ezinzima ngakumbi, amayeza acinezela amajoni omzimba afana ne-methotrexate okanye i-corticosteroids anokufuneka. Kutshanje, unyango lwebhayoloji (rituximab, omalizumab, interleukin-1 inhibitors) lubonise isithembiso seemeko ezinzima.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Indoda eneminyaka engama-35 ubudala yafika kunye nembali ye-15 yeentsuku ezibomvu ezibomvu, ezibuhlungu ezibuhlungu emathangeni nasemilenzeni, kunye nentlungu edibeneyo. Wayenosulelo lomgudu womchamo kangangeveki phambi kokuba kuvele irhashalala. Ulusu lwakhe lwalubonakala luthambileyo, lumile okwesangqa, lunamacwecwe abomvu kumacala omabini amathanga nemilenze. Wanikwa i-prednisolone yomlomo (i-40mg / ngosuku) ngeveki kunye ne-antihistamine engapheliyo (fexofenadine) . Kwisithuba esingangeveki, zonke iirhashalala zanyamalala ngokupheleleyo. Akuzange kuphinde kubekho irhashalala kwiinyanga ezi-6 ezilandelayo zokujongwa rhoqo.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.